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Abstract— The synthesis of cyclic peptoids containing an indole hydrophobic scaffold has been 
realised through the ring-closing metathesis of diallylated precursors. The precursors and their cyclic 
counterparts possessed poor antibacterial activity in contrast to previously reported cyclic peptoids 
containing hydrophobic scaffolds.   
 
——— 
* Corresponding author. Tel.: +61 2 4221 4692; fax: +61 2 4221 4287; e-mail: keller@uow.edu.au. 
1. Introduction 
The development and clinical application of antibiotics in the late 1930’s enabled the control of the 
majority of bacterial infections. However, by the late 1950’s up to 85% of clinical staphylococci isolates 
were found to be penicillin resistant.1 Bacteria now have the ability to pass genetic information onto 
different strains leading to the widespread resistance of bacteria to many of the currently used 
antibiotics. The recent report of resistance to vancomycin is of the greatest concern as it represents the 
last line of defence against infections of multidrug resistant staphylococci and enterococci.2 Resistance 
to vancomycin was first documented in 1988,3 from hospitals in both Europe,4 and the USA.5 This 
emergence of vancomycin resistant enterococci (VRE) is significant and points to the prospect of 
widespread vancomycin resistance to multi-drug resistant pathogenic bacteria such as methicillin 
resistant Staphylococcus aureus (MRSA). ‘Super-resistant’ bacterial strains such as these have been 
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demonstrated in a controlled environment, highlighting the ease in which resistance may spread to 
pathogenic bacteria,3 and there are now cases of fully resistant isolates of Staphyloccocus aureus being 
reported.6  
 
The advent of untreatable multidrug resistant bacteria has created an unmet medical need to create new 
antibacterial agents. The development of new therapeutic agents is even more critical considering only 
one new class of antibacterial agents, the oxazolidinone linezolid,7 has been launched in the last 35 
years, and already resistance to this therapeutic has started to emerge.8-10  
 
With the increasing spread of antibacterial resistance, including resistance by pathogenic bacteria to 
vancomycin, there is a compelling imperative for new antibacterials.10 We have undertaken a program 
investigating the design and synthesis of cyclic peptoids linked by a hydrophobic scaffold as potential 
antibacterial  agents, and thus far, have shown the binaphthyl11 and carbazole scaffolds12,13 within these 
cyclic peptoids produce antibacterial  agents, for example 1 and 2, of reasonable potency (Figure 1). 
Therefore, as part of this programme targeting the design and synthesis of new peptoid derivatives as 
antibacterial agents and attempting to address the resistance mechanism against vancomycin, we 
investigated the synthesis of some acyclic and cyclic indole-based derivatives. These derivatives were 
designed to explore the effect on activity of a smaller rigid scaffold in which the indolic nitrogen was to 




















MIC 7 μg/mL MIC 15 μg/mL
1 2
 
Figure 1. Cyclic peptoids containing a hydrophobic scaffold that show anti-bacterial activity.11-13 MIC = 
minimum inhibitory concentration and activities are against a wild type S. aureus strain. 
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2. Results and Discussion 
2.1. Synthesis of Indole-Based Peptoids 
The synthesis of cyclic peptoids incorporating an indolic scaffold is outlined in Scheme 1. The strategy 
involved the addition of a dipeptide to an indole unit that contained a linking group at C3 as well as 
utilising the N1 position as a linking group via the addition of an allyl substituent. Cyclisation was to be 
achieved using reliable ring-closing metathesis (RCM) reactions.11-14 While the choice of dipeptide to 
use is potentially extensive, a limitation is that one of the amino acids must also contain an additional 
allyl group such that the ring-closing metathesis reaction is possible. Cyclic peptoids of different sizes 
were synthesised by extending the number of methylene linkers between the indole C3 position and the 
first carboxylic acid unit. 
 
Therefore, treatment of commercially available indole acids 3-5 with base, followed by an excess of 
allyl bromide gave a mixture of both the allyl esters 9-11 and the diallylated products 6-8 (Scheme 1). 
Subsequent saponification with LiOH yielded the desired carboxylic acids 12-14. This 2-step process 
was the most efficient method of N-allylation in the presence of the carboxylic acid, although with the 
lengthening of the C3 chain, the yield of the monoallyl ester byproducts, 10 and 11, became more 
prominent. The coupling of the dipeptide, L-allylGlyOMe-D-Lys 15, to 12-14 was achieved through 
well established EDCI coupling. The key RCM of dienes 16-18 proceeded efficiently in the case of the 
products 19-21 producing a discernible mixture of both E and Z isomers, which could not be separated 
by silica gel chromatography. In contrast, the yield of 21 was lower, presumably due to the difficulties in 
forming the larger ring. However, further optimisation of this reaction may improve this outcome. The 
structures of the cyclised products were elucidated on the basis of high resolution mass spectrometric 
and NMR spectroscopic evidence. In the 1H-NMR spectrum of 19, for example, the signal ascribed to  

































3, n = 1
4, n = 2
5, n = 3
a
6, n = 1, R = allyl (71%)  +  9,   n = 1, R = H (14%)
7, n = 2, R = allyl (25%)  +  10, n = 2, R = H (29%)
8, n = 3, R = allyl (33%)  +  11, n = 3, R = H (23%)
b
12, n = 1 (71%)
13, n = 2 (43%)
14, n = 3 (91%)
16, n = 1 (43%)
17, n = 2 (53%)
18, n = 3 (28%)
c d
+
19, n = 1, R = Boc (58%)
20, n = 2, R = Boc (100%)
21, n = 3, R = Boc (13%)
22, n = 1, R = H.HCl (86%)
23, n = 2, R = H.HCl (91%)



























Scheme 1. a) NaH (2.2 equiv.), allyl bromide (2.5 equiv.), DMF, RT, 12h. b) 0.15 M LiOH, THF, water, 
0 °C. c) L-allylGlyOMe-D-Lys 15, EDCI, DMAP, MeCN, CH Cl , RT, 18 h. d) 10 mol% Grubbs I 
catalyst, CH Cl , reflux 18 h. e) TFA, CH Cl , RT, 2 h. 
2 2
2 2 2 2
 
H3 appeared as a doublet of triplets at δ5.52 (J = 15, 6 Hz) with an associated multiplet at δ 5.90 
assigned as either the corresponding Z isomer or rotamers. The larger coupling constants of 15-16 Hz for 
H3 in 19 and 20 were consistent with the E-geometry of the major isomers of these compounds. 
Unfortunately, J3,4 for 22 could not be determined due to peak overlap. The E/Z ratio of 19, 20, and 21 
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was thus estimated as 4:1, 7:3 and 3:2 respectively, from 1H-NMR analysis. Final unmasking of the 
lysine side chain and crystallisation from diethyl ether.HCl solution gave the cyclic peptoids as their 
hydrochloride salts 22-24. 
 
The corresponding hydrochloride salts of the deprotected acyclic precursors (25-27) were also 
synthesised using typical acidic conditions starting from 15-17 (Scheme 2). Further, the corresponding 
guanidine derivatives of the cyclic peptoids 31-33 were also produced via 28-30, again using standard 
reaction conditions starting from 22-24, and using N,N′-diBoc-N-triflylguanidine in the key guanidation 









16, n = 1
17, n = 2




25, n = 1 (100%)
26, n = 2 (80%)
27, n = 3 (47%)  











28, n = 1, (46%)
29, n = 2, (84%)
30, n = 3, (70%)
22, n = 1
23, n = 2













31, n = 1, (11%)
32, n = 2, (73%)














Scheme 3. Reagents: a) N,N’-diBoc-N-triflylguanidine, Et3N, CH2Cl2. b) TFA, CH2Cl2. 
 
  6 
The chemical yields for all transformations were not optimised, leading to some inconsistencies in 
outcome for individual steps. However, the ease of formation of all derivatives ensured facile access to 
the desired cyclic derivatives for testing. 
2.2. Antibacterial Results 
The synthesised cyclic dipeptoids 22-24 and 31-33 were tested against the Gram-positive bacterium S. 
aureus ATCC6538 and showed MIC values greater than ≥ 125 μg/mL, indicating that these indole-based 
scaffolds are not good hydrophobic units for incorporation into the design program for antibacterial  
development. In view of the success of some of our previous cyclic peptoid structures that showed 
antibacterial activities of MIC 7 μg/mL and 15 μg/mL for 1 and 2, respectively (Figure 1), the biological 
results for the new indole-based molecules were disappointing. The binaphthyl scaffold would contain a 
degree of flexibility by comparison, and might be able to orientate more easily into an active 
conformation. However, the carbazole scaffold in 2 is quite rigid, a conformational characteristic which 
is anticipated to be closer to that shown by the indole-based molecules. Although the mode of action of 
this class of compounds has not yet been established, we anticipate that the lack of activity for the new 
derivatives must arise from the wrong 3-dimensional array of the relevant substituents. The smaller 
macrocyclic ring sizes in 22-24 compared with those in 1 or 2 may also be relevant in this context. 
Given that the same dipeptide is used in all three cases, we therefore presume that the presence of a 
particular hydrophobic moiety becomes an additional important element in establishing antibacterial 
activity, and that the indole scaffold itself is simply not appropriate. We are currently investigating other 
hydrophobic scaffolds in order to improve antibacterial activity. 
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All NMR spectra were determined in CDCl3 solution at 300 MHz (1H NMR) or 75 MHz (13C NMR) 
unless otherwise indicated. On occasions, the 13C and 1H NMR spectra indicated the presence of a minor 
component which could be either rotamers or geometric isomers through the doubling of peaks. These 
have been reported and are assigned with an asterix (*). Petroleum spirit has a bp range of 40-60 °C. 
TLC was performed on Merck Al-backed plates. Other general experimental procedures have been 
reported previously.13
3.2 Allylation of Indolyl-3-carboxylates – General Procedure A 
Allyl 1-allyl-1H-indole-3-acetate (6) and Allyl 1H-indole-3-acetate (9) 
To a suspension of sodium hydride (1.0 g, 25.1 mmol, 60% in paraffin), that had been washed twice 
with petroleum spirit under a N2 atmosphere, in dry DMF (8 mL) was added a solution of 1H-indole 
acetic acid 3 (2.00 g, 11.4 mmol) in DMF (5 mL) under N2 at rt  The mixture was stirred for 30 min 
before allyl bromide (2.5 mL, 28.6 mmol) was added dropwise. The reaction mixture was stirred for 18 
h, concentrated and the residue partitioned between water (20 mL) and diethyl ether (2 x 20 mL). The 
combined extracts were washed (water), dried (Na2SO4) and concentrated. The crude product was 
subjected to flash silica gel column chromatography (20% CH2Cl2 in petroleum spirit) to produce 6 
(2.08 g, 71%) as an oil. TLC (petroleum spirit/DCM 5:1) Rf = 0.89; 1H NMR δ = 7.68 (d, J = 8 Hz, 1 H, 
ArH4), 7.34 (d, J = 8 Hz, 1 H, ArH7), 7.26 (apparent t, J = 7 Hz, 1 H, ArH6), 7.18 (apparent t, J = 7 Hz, 
1 H, ArH5), 7.14 (s, 1 H, ArH2), 5.99 (m, 2 H, 2×CH=CH2), 5.37-5.10 (m, 4 H, 2×CH=CH2), 4.70 (d, J 
= 5 Hz, 2 H, CH2CH=CH2), 4.66 (d, J = 5 Hz, 2 H, CH2CH=CH2), 3.86 (s, 2 H, CH2CO); 13C NMR δ = 
171.1 (CO), 136.0 (ArC), 133.2 and 131.9 (CH=CH2), 127.6 (ArC), 126.6, 121.5 and 119.1 (ArCH), 
118.9 (CH=CH2), 117.9 (ArCH), 117.1 (CH=CH2), 109.4 (ArCH), 106.9 (ArC), 65.2 (OCH2), 48.6 
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(NCH2), 31.1 (CH2); MS (CI) m/z 256 (100% MH+). HRMS (CI) calcd for C16H18NO2: 256.1338; found: 
256.1338. 
Further elution with 50% CH2Cl2 in petroleum spirit gave 9 (0.35 g, 14%). TLC (petroleum 
spirit/CH2Cl2 1:1) Rf = 0.54; 1H NMR δ = 8.2 (1H, bs, NH), 7.68 (d, J = 7Hz, 1 H, ArH4), 7.31-7.17 (m, 
3 H, ArH7,6,5), 7.01 (d, J = 3 Hz, 1 H, ArH2), 5.98 (ddt, J = 17, 10, 5 Hz, 1 H, CH=CH2), 5.35 (dd, J = 
16, 1 Hz, 2 H, CH=CH2), 5.27* (dd, J = 10, 1 Hz, 2 H, CH=CH2), 4.68 (dd, J = 5, 1 Hz, 2 H, 
NCH2CH=CH2), 3.86 (s, 2 H, CH2CO); 13C NMR δ = 171.2 (CO), 135.9 (ArC), 132.0 (CH=CH2), 127.0 
(ArC), 123.3, 121.9 and 119.4 (ArCH), 118.6 (CH=CH2), 118.2 (ArCH), 111.2 (ArCH), 107.7 (ArC), 
65.4 (OCH2), 31.2 (CH2); MS (CI) m/z 216 (100% MH+). HRMS (CI) calcd for C13H14NO2: 216.1024; 
found: 216.1021.  
Allyl 1-allyl-1H-indole-3-propanoate (7) and Allyl 1H-indole-3-propanoate (10) 
These were prepared by general procedure A using 1H-indole-3-propanoic acid 4 (2.36 g, 12.5 mmol), 
NaH (660 mg, 16.5 mmol) allyl bromide (2.7 mL, 31.2 mmol) and DMF (9 mL). The crude residue was 
subjected to flash silica gel column chromatography (20% CHCL2 in petroleum spirit) to give 7 (0.84 g, 
25%) as an oil. TLC (petroleum spirit/DCM 5:1) Rf = 0.92; 1H NMR δ = 7.67 (d, J = 8 Hz, 1 H, ArH4), 
7.34 (d, J = 8 Hz, 1 H, ArH7), 7.27 (t, J = 8 Hz, 1 H, ArH6), 7.18 (t, J = 8 Hz, 1 H, ArH5), 6.96, (s, 1 H, 
ArH2), 6.07-5.90 (m, 2 H, 2×CH=CH2), 5.38-5.08 (m, 4 H, CH=CH2), 4.69 (d, J = 5 Hz, 2 H, 
CH2CH=CH2), 4.65 (d, J = 5 Hz, 2 H, CH2CH=CH2), 3.19 (t, J = 8 Hz, 2 H, CH2CH2CO), 2.81 (t, J = 8 
Hz, 2 H, CH2CO); 13C NMR δ = 172.8 (CO), 136.2 (ArC), 133.5 and 132.1 (CH=CH2), 127.6 (ArC), 
125.1 and 121.5 (ArCH), 118.8 (ArCH), 118.7 (CH=CH2), 118.0 (ArCH) 116.9 (CH=CH2), 113.6 
(ArC), 109.5 (ArCH), 64.9 (OCH2), 48.4 (NCH2), 34.9 and 20.5 (CH2); MS (ES) m/z 270 (100% MH+), 
212 (25%), 170 (88%). HRMS (ES) calcd for C17H19NO2: 269.1416; found: 269.1412.  
Further elution with 50% petroleum spirit in DCM gave 10 (0.84 g, 29%): TLC (petroleum spirit/DCM 
1:2) Rf = 0.75; 1H NMR δ = 8.16 (br s, 1 H, NH), 7.70 (dd, J = 8, 2 Hz, 1 H, ArH4), 7.36 (dd, J = 8, 2 
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Hz, 1 H, ArH7), 7.28 (dd, J = 8 Hz, 1 H, ArH6), 7.22 (dt, J = 8, 2 Hz, 1 H, ArH5), 6.98 (d, J = 3 Hz, 1 
H, ArH2), 5.98 (ddt, J = 17, 10, 6 Hz, 1 H, CH=CH2), 5.37 (ddd, J = 17, 2, 1 Hz, 2 H, CH=CH2), 5.30* 
(ddd, J = 10, 2, 1 Hz, 2 H, CH=CH2), 4.68 (2×t, J = 6 Hz, 2 H, CH2CH=CH2), 3.22 (t, J = 8 Hz, 2 H, 
CH2CO), 2.85 (t, J = 8 Hz, 2 H, CH2CH2CO); 13C NMR δ = 173.1 (CO), 136.1 (ArC), 132.0 (CH=CH2), 
126.9 (ArC), 121.7, 121.4 and 119.0 (ArCH), 118.4 (CH=CH2), 118.0 (ArCH), 114.3 (ArC), 111.1 
(ArCH), 65.0 (OCH2), 34.7 and 20.4 (CH2); MS (ES) m/z 230 (100% MH+), 172 (55%), 130 (75%). 
HRMS (ES) calcd for C14H15NO2: 229.1103; found: 229.1100.  
Allyl 1-allyl-1H-indole-3-butanoate (8) and allyl 1H-indole-3-butanoate (11) 
These were prepared by general procedure A using 1H-indole-3-butanoic acid 5 (1.00 g, 4.9 mmol), 
NaH (217 mg, 5.4 mg), allyl bromide (1.1 mL, 12.7 mmol) and DMF (6 mL). The crude product was 
subjected to flash silica gel column chromatography (50% DCM in petroleum spirit) to give 8 (0.46 g, 
33%) as an oil. TLC (petroleum spirit/DCM 2:1) Rf = 0.91; 1H NMR δ = 7.58 (dt, J = 8, 1 Hz, 1 H, 
ArH4), 7.24 (dd, J = 8, 1 Hz, 1 H, ArH7), 7.17 (dt, J = 8, 1 Hz, 1 H, ArH6), 7.08 (dt, J = 8, 1 Hz, 1 H, 
ArH5), 6.84 (s, 1 H, ArH2), 5.90 (m, 2 H, 2×CH=CH2), 5.28 (ddd, J = 17, 2, 1 Hz, 2 H, CH=CH2), 
5.19* (ddd, J = 11, 2, 1 Hz, 2 H, CH=CH2), 5.13* (ddd, J = 10, 2, 1 Hz, 2 H, CH=CH2), 5.03 (ddd, J = 
18, 2, 1 Hz, 2 H, CH=CH2), 4.57 (dd, J = 5, 1 Hz, 4 H, CH2CH=CH2), 2.78 (t, J = 7 Hz, 2 H, 
CH2CH2CH2CO), 2.38 (t, J = 7 Hz, 2 H, CH2CO), 2.03 (pent, J = 7 Hz, 2 H, CH2CH2CO); 13C NMR δ = 
173.2 (CO), 136.3 (ArC), 133.5 and 132.2 (CH=CH2), 127.9 (ArC), 125.1, 121.4 and 118.9 (ArCH), 
118.6 (CH=CH2), 118.0 (ArCH) 116.9 (CH=CH2), 114.3 (ArC), 109.4 (ArCH), 64.8 (OCH2), 48.4 
(NCH2), 33.7, 25.3 and 24.3 (CH2); MS (CI) m/z 284 (100% MH+). HRMS (CI) calcd for C18H22NO2: 
284.1650; found: 284.1639.  
Further elution with 50% petroleum spirit in DCM gave 11 (0.27 g, 23%). TLC (petroleum spirit/DCM 
1:2) Rf = 0.66; 1H NMR δ = 8.0 (br s, 1 H, NH), 7.59 (d, J  = 8 Hz, 1 H, ArH4), 7.34 (d, J  = 8 Hz, 1 H, 
ArH7), 7.17 (t, J = 8 Hz, 1 H, ArH6), 7.09 (t, J = 8 Hz, 1 H, ArH5), 6.97 (d, J = 2 Hz, 1 H, ArH2), 5.89 
  10
(ddt, J = 10, 5, 1 Hz, 1 H, CH=CH2), 5.29 (dd, J = 16, 1 Hz, 2 H, CH=CH2), 5.21* (dd, J = 10, 1 Hz, 2 
H, CH=CH2), 4.55 (d, J = 6 Hz, 2 H, CH2CH=CH2), 2.80 (t, J = 7 Hz, 2 H, CH2CH2CH2CO), 2.40 (t, J = 
7 Hz, 2 H, CH2CO), 2.05 (t, J = 7 Hz, 2 H, CH2CH2CO); 13C NMR δ = 173.2 (CO), 136.2 (ArC), 132.1 
(CH=CH2), 127.3 (ArC), 121.8, 121.3 and 119.1 (ArCH), 118.8 (CH=CH2), 118.1 (ArCH), 115.5 (ArC), 
111.0 (ArCH), 65.0 (OCH2), 33.9, 29.8, 25.4 and 24.5 (CH2); MS (CI) m/z 244 (100% MH+), 186 (45% 
M+-OCH2CH=CH2). HRMS (CI) calcd for C15H18NO2: 244.1338; found: 244.1332. 
3.2 Hydrolysis of Allyl Esters – General Procedure B 
1-Allyl-1H-indole-3-acetic acid (12) 
To a solution of 6 (1.84 g, 7.2 mmol) in THF/water (5:2, 35 mL) was added lithium hydroxide (0.3 g, 
12.5 mmol) and the reaction mixture was placed in an ice bath and stirred at 0 °C for 3 h. It was then 
concentrated and the residue was partitioned between diethyl ether and water (2 x 30 mL). The 
combined aqueous layers were acidified with HCl (10%) to pH < 2. The aqueous layer was then 
saturated with sodium chloride and extracted with DCM (20 mL), dried (Na2SO4) and evaporated to give 
12 (1.1 g, 71%) as an oil. 1H NMR δ = 7.60 (d, J = 8 Hz, 1 H, ArH4), 7.30 (d, J = 8 Hz, 1 H, ArH7), 
7.22 (dt, J = 8, 1 Hz, 1 H, ArH6), 7.13 (dt, J = 8, 1 Hz, 1 H, ArH5), 7.08 (s, 1 H, ArH2), 5.98 (ddt, J = 
17, 11, 5 Hz, 1 H, CH=CH2), 5.20* (dd, J = 9, 1 Hz, 2 H, CH=CH2), 5.11 (dd, J = 16, 1 Hz, 2 H, 
CH=CH2), 4.68 (dd, J = 5, 1 Hz, 2 H, NCH2CH=CH2), 3.80 (s, 2 H, CH2CO); 13C NMR δ = 177.5 (CO), 
136.1 (ArC), 133.2 (CH=CH2), 127.6 (ArC), 126.8, 121.8 and 119.3 (ArCH), 118.9 (CH=CH2), 117.4 
and 109.6 (ArCH), 106.4 (ArC), 48.8 (NCH2), 31.0 (CH2); MS (CI) m/z 216 (100% MH+). HRMS (CI) 
calcd for C13H14NO2: 216.1024; found: 216.1039.  
1-Allyl-1H-indole-3-propanoic acid (13) 
This was prepared by general procedure B from 7 (0.650 g, 2.4 mmol), LiOH (0.220 g, 9.2 mmol) and 
35 mL of solvent to give 13 (0.24 g, 43%) as an oil. 1H NMR δ 7.59 (d, J = 8 Hz, 1 H, ArH4), 7.34 (d, J 
= 8 Hz, 1 H, ArH7), 7.16-7.01 (m, 3 H, ArH2,5,6), 6.07-5.94 (m, 1 H, CH=CH2), 5.12* (dd, J = 10, 1 
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Hz, 2 H, CH=CH2), 5.04 (dd, J = 17, 1 Hz, 2 H, CH=CH2), 4.77 (d, J = 3Hz, 2 H, NCH2CH=CH2), 3.04 
(t, J = 10 Hz, 2 H, CH2CH2CO), 2.68 (t, J = 8 Hz, 2 H, CH2CO); 13C NMR δ = 179.3 (CO), 136.4 
(ArC), 133.5 (CH=CH2), 127.7 (ArC), 125.2, 121.7 and 118.9 (ArCH), 118.8 (CH=CH2), 117.1 (ArCH), 
113.5 (ArC), 109.6 (ArCH), 48.6 (NCH2), 31.5 and 20.3 (CH2); MS (CI) m/z 230 (100% MH+); (ES) 
170 (M+-CH2COOH). HRMS (CI) calcd for C14H16NO2: 230.1181; found: 230.1181. 
1-Allyl-1H-indole-3-butanoic acid (14) 
This was prepared by general procedure B from 8 (0.460 g, 1.6 mmol), LiOH (0.220 g, 9.2 mmol) and 
solvent (35 mL) to give 14 (0.36 g, 91%) as an oil. 1H NMR δ = 7.61 (d, J = 8 Hz, 1 H, ArH4), 7.30 (d, 
J = 8 Hz, 1 H, ArH7), 7.21 (t, J = 8 Hz, 1 H, ArH6), 7.12 (t, J = 8 Hz, 1 H, ArH5), 6.91 (s, 1 H, ArH2), 
5.99 (ddt, J = 17, 11, 5 Hz, 1 H, CH=CH2), 5.20* (dd, J = 10, 2 Hz, 2 H, CH=CH2), 5.10 (dd, J = 17, 2 
Hz, 2 H, CH=CH2), 4.69 (d, J = 5 Hz, 2 H, NCH2CH=CH2), 2.84 (t, J = 7 Hz, 2 H, CH2CH2CH2CO), 
2.45 (t, J = 7 Hz, 2 H, CH2CO), 2.07 (t, J = 7 Hz, 2 H, CH2CH2CO); 13C NMR δ = 179.7 (CO), 136.4 
(ArC), 133.6 (CH=CH2), 127.9 (ArC), 125.3, 121.5 and 119.0 (ArCH), 118.8 (CH=CH2), 117.0 (ArCH), 
114.3 (ArC), 109.5 (ArCH), 48.6 (NCH2), 33.5, 15.1 and 24.3 (CH2); MS (ES) m/z 244 (100% MH+), 
226 (55% MH+-H2O). HRMS (CI) calcd for C15H18NO2: 244.1337; found: 244.1336. 
3.3 Preparation of  
Methyl (2S,5R)-2-Allyl-5-amino-3-aza-9-(tert-butoxycarbonyl)amino-4-oxononanoate -  
L-allylGlyOMe-D-Lys (15) 
To a mixture of N-Fmoc-D-Lys(Boc)OH (1.22 g, 2.61 mmol), methyl (S)-2-amino-4-pentenoate 
hydrochloride (430 mg, 2.61 mmol) and 4-dimethylaminopyridine (DMAP) (1 crystal) was added dry 
DCM (10 mL) followed by N,N-diisopropylethylamine (0.45 mL, 2.61 mmol) under a nitrogen 
atmosphere. The mixture was stirred at rt for 5 min before EDCI (500 mg, 2.61 mmol) was added, and 
the reaction mixture was then stirred for 23.5 h. After this period, the reaction mixture was diluted with 
DCM, washed with brine and then water, and the DCM layer was dried and evaporated. The crude 
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product was purified by column chromatography (PS with gradient elution to DCM:MeOH 10:1) to 
afford the protected coupled dipeptide (1.25 g, 2.16 mmol, 83%) as a pale yellow solid, mp 118-119 °C. 
Rf: 0.52 in 10% MeOH in DCM. 1H NMR δ 7.73 (d, J = 7.5 Hz, 2H, ArH4 and ArH5), 7.56 (d, J = 7.2 
Hz, 2H, ArH1 and ArH8), 7.36 (dd, J = 7.3, 7.2 Hz, 2H, ArH3 and ArH6), 7.27 (dd, J = 7.3, 7.2 Hz, 2H, 
ArH2 and ArH7), 6.82 (d, J = 6.6 Hz, 1H, NH-3), 5.76-5.52 (m, 2H, CH2CH=CH2 and NHBoc), 5.05 (d, 
J = 16.5 Hz, 1H, CH2CH=CHH), 5.04 (d, J = 10.5 Hz, 1H, CH2CH=CHH), 4.64 (m, 2H, NCH-2 and 
NHFmoc), 4.35 (d, J 6.9 Hz, 2H, OCH2), 4.18 (t, J = 6.9 Hz, 2H, Fmoc CH and NCH-5 (obscured)), 
3.67 (s, 3H, OCH3), 3.07 (m, 2H, NCH2(CH2)3), 2.50 (m, 2H, CH2CH=CH2), 1.82 (m, N(CH2)3CH2), 
1.63 (m, N(CH2)3CH2), 1.53-1.25 (m, 4H, NCH2(CH2)2CH2), 1.40 (s, 9H, C(CH3)3). 13C NMR δ 171.8 
(COOCH3), 171.4 (CO-4), 156.2 (Fmoc CO), 156.1 (Boc CO), 143.7 and 143.6 (ArC8a and ArC9a), 
141.2 (ArC4a and ArC4b), 132.0 (CH2CH=CH2), 127.7 (ArCH3 and ArCH6), 127.0 (ArCH2 and 
ArCH7), 125.0 (ArCH1 and ArCH8), 119.9 (ArCH4 and ArCH5), 119.3 (CH2CH=CH2), 79.1 
(C(CH3)3), 67.1 (OCH2), 54.6 (NCH5), 52.4 (OCH3), 51.5 (NCH2), 47.0 (Fmoc CH), 39.8 
(NCH2(CH2)3), 36.3 (CH2CH=CH2), 32.1 (N(CH2)3CH2), 29.6 (NCH2CH2(CH2)2), 28.3 (C(CH3)3), 22.3 
(N(CH2)2CH2CH2). MS (ES) m/z 580 (100% MH+), 524 (88%), 480 (66%). HRMS (ES) calcd for 
C32H42N3O7: 580.3023; found: 580.3002.  
To a solution of the protected dipeptide (500 mg, 0.86 mmol) in anhydrous CH3CN (10 mL) was added 
a solution of piperidine (0.04 mL, 0.43 mmol) in anhydrous CH3CN under a nitrogen atmosphere, and 
the reaction mixture was stirred at rt for 3.25 h. The reaction solvent was evaporated and the crude 
product was purified by column chromatography (PS with gradient elution to DCM:MeOH 10:1) to 
afford 15 (308 mg, 0.86 mmol, 100%) as a yellow oil. Rf: 0.24 in 10% MeOH in DCM. 1H NMR δ 7.66 
(d, J = 8.1 Hz, 1H, NH-3), 5.60 (ddt, J = 17.1, 10.5, 6.9 Hz, 1H, CH2CH=CH2), 5.03 (dd, J = 16.5, 1.2 
Hz, 1H, CH2CH=CHH), 5.02, (dd, J = 10.8, 0.9 Hz, 1H, CH2CH=CHH), 4.79 (br s, 1H, NHBoc), 4.52 
(dt, J = 8.1, 6.0 Hz, 1H, NCH-2), 3.64* (s, OCH3), 3.64 (s, OCH3), 3.27 (m, 1H, NCH-5), 3.01 (m, 2H, 
   13
NCH2(CH2)3), 2.45 (m, 2H, CH2CH=CH2), 1.80-1.64 (m, NH2 and N(CH2)3CH2), 1.56-1.25 (m, 
NCH2(CH2)3), 1.33 (s, 9H, C(CH3)3). 13C NMR δ 174.9 (COOCH3), 172.0 (CO-4), 156.0 (Boc CO), 
132.2 (CH2CH=CH2), 118.8 (CH2CH=CH2), 78.8 (C(CH3)3), 54.7 (NCH-5), 52.1 (OCH3), 51.1 (NCH-
2), 39.9 (NCH2(CH2)3), 36.1 (CH2CH=CH2), 34.3 (N(CH2)3CH2), 29.6 (NCH2CH2(CH2)2), 28.2 
(C(CH3)3), 22.4 (N(CH2)2CH2CH2). MS (ES) m/z 358 (89% MH+), 302 (100%), 258 (93%). HRMS (ES) 
calcd for C17H32N3O5: 358.2342; found: 358.2329.  
 
3.4 Coupling of Indole Carboxylates with Dipeptides – General Procedure C. 
Methyl (2S,5R)-2-allyl-8-(N-allyl-1H-indol-3-yl)-3,6-diaza-5-(tert-butoxycarbonylamino)butyl-4,7-
dioxooctanoate (16) 
To a solution of 12 (0.048 g, 0.2 mmol) in DCM (3 mL) was added 15 (0.080 g, 0.22 mmol) in 
acetonitrile (3 mL) and a catalytic amount of DMAP. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide 
(0.043 g, 0.2 mmol) was then added and the mixture was stirred for 18 h under a N2 atmosphere at rt. 
The solvents were evaporated and the mixture was partitioned between DCM and water. The DCM layer 
was separated and washed several times with water, dried (Na2SO4) and evaporated. The crude product 
was chromatographed on a flash silica gel column (2% methanol in DCM) to produce 16 (0.090 g, 43%) 
as a solid. TLC (DCM/MeOH 50:1) Rf = 0.22; 1H NMR δ = 7.52 (d, J = 8 Hz, 1 H, ArH4), 7.29 (d, J = 8 
Hz, 1 H, ArH7), 7.20 (t, J = 8 Hz, 1 H, ArH6), 7.10 (t, J = 8 Hz, 1 H, ArH5), 7.06 (s, 1 H, ArH2), 6.78 
(d, J = 8 Hz, 1 H, NH-3), 6.21 (d, J = 8 Hz, 1 H, NH-6), 5.97 (ddt, J = 17, 11, 5 Hz, 1 H, 
NCH2CH=CH2), 5.61 (m, 1 H, CHCH2CH=CH2), 5.18 (d, J = 10 Hz, 1 H, CH=CHH), 5.09-5.04 (m, 3 
H, CH=CH2 + CH=CHH), 4.69 (d, J = 6 Hz, 2 H, NCH2-CH=CH2), 4.53 (m, 1 H, H2), 4.43 (m, 1 H 
H5), 3.72 (s, 2 H, H8), 3.68 (s, 3 H, OCH3), 2.93 (d, J = 5 Hz, 2 H, NCH2(CH2)3), 2.53-2.35 (m, 2 H, 
CHCH2CH=CH2), 1.77-1.66 (m, 1 H, N(CH2)3CH2) 1.41 (s, 9 H, C(CH3)3), 1.45-1.27 (m, 4 H, 
N(CH2)3CH2 + NCH2CH2(CH2)2), 1.15-1.08 (m, 2 H, N(CH2)2CH2CH2); 13C NMR δ = 171.7 (7-CO), 
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171.5 (COOCH3), 170.9 (5-CO), 155.8 (NCO2But), 136.4 (ArC7), 133.1 (NCH2 CH=CH2), 132.0 
(CH2CH=CH2), 127.4 (ArC3a), 127.2 (ArC2), 122.1 (ArC6), 119.6 (ArC4), 119.1 (CH2CH=CH2), 118.7 
(ArCH5), 117.4 (NCH2CH=CH2), 109.8 (ArCH7), 107.4 (ArC3), 79.1 (OCMe3), 52.7 (C2), 52.4 
(OCH3), 51.6 (C5), 48.8 (NCH2CH=CH2), 40.1 (NCH2(CH2)3), 36.3 (C8), 33.3 (CHCH2CH=CH2), 31.5 
(N(CH2)3CH2), 29.5 (NCH2CH2(CH2)2), 28.5 (C(CH3)3), 22.5 (N(CH2)2CH2CH2); MS (ES) m/z 555 
(95% MH+), 499 (89%), 455 (100%). HRMS (ES) calcd for C30H43N4O6: 555.3184; found: 555.3163. 
Methyl (2S,5R)-2-allyl-9-(N-allyl-1H-indol-3-yl)-3,6-diaza-5-(tert-butoxycarbonylamino)butyl-4,7-
dioxononanoate (17) 
This was prepared by general procedure C using 13 (0.220 g, 0.96 mmol), 15 (0.210 g), DCM (3 mL), 
AcCN (6 mL) and EDCI (0.114 g), to give 17 (0.290 g, 53%). TLC (DCM/MeOH 50:1) Rf = 0.45; 1H 
NMR (CDCl3, 500MHz) δ = 7.57 (d, J = 8 Hz, 1 H, H4), 7.25 (d, J = 8 Hz, 1 H, H7), 7.17 (dd, J = 8, 4 
Hz, 1 H, H6), 7.07 (dd, J = 8, 4 Hz, 1 H, H5), 7.01 (d, J = 4 Hz, 1 H, NH-3), 6.88 (s, 1 H, H2), 6.49 (d, J 
= 4 Hz, 1 H, NH-6), 5.97-5.88 (m, 1 H, NCH2CH=CH2), 5.65 (ddt, J = 17, 10, 4 Hz, 1 H, CH2CH=CH2), 
5.15-5.03 (m, 4 H, 2×CH=CH2), 4.67-4.61 (m, 2 H, NCH2CH=CH2 and NHBoc), 4.62 (m, 1 H, H2), 
4.47 (dd, J = 14, 7 Hz, 1 H, H5), 3.69 (s, 3 H, OCH3), 3.15-3.00 (m, 2 H, H9), 3.05-2.93 (m, 2 H, 
NCH2(CH2)3), 2.72 (m, 1 H, H8), 2.60 (m, 1 H, H8), 2.60-2.52 (m, 1 H, CH-CH2-CH=CH2), 1.74-1.66 
(m, 1 H, N(CH2)3CH2), 1.54-1.44 (m, 2 H, N(CH2)3CH2), 1.41 (s, 9 H, C(CH3)3), 1.42-1.34 (m, 2 H, 
NCH2(CH2)2), 1.22-1.14 (m, 2 H, N(CH2)2CH2CH2); 13C NMR δ = 176.8* (7-CO), 172.9 (7-CO), 171.5 
(COOCH3), 171.5 (4-CO), 155.9 (N-CO2But), 136.3 (C7), 133.4 (CH=CH2), 132.0 (CH=CH2), 127.7 
(ArC3a), 125.2 (ArC2), 125.0* (ArC2), 121.5 (ArC6), 119.1 (CH2CH=CH2), 118.9 (ArC4 and ArC5), 
118.8* (ArC4), 118.7* (ArC5), 117.0 (NCH2CH=CH2), 113.7* (ArC3), 113.6 (ArC3), 109.4 (ArC7), 
79.0 (OCMe3), 52.7 (C5), 52.4 (OCH3), 51.7 (C2), 48.6 (NCH2-CH=CH2), 40.0 (N-CH2(CH2)3), 37.2 
(H8), 36.3 (CHCH2-CH=CH2), 34.8* (H8), 31.9 (N(CH2)3CH2), 29.5 (NCH2-CH2(CH2)2), 28.4 
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(C(CH3)3), 22.4 (N(CH2)2CH2CH2), 21.3 (C9), 20.5* (C9); MS (ES) m/z 569 (100% MH+), 513 (49% 
MH+-C(Me3)), 469 (64% MH+-Boc). HRMS (ES) calcd for C31H45N4O6: 569.3339; found: 569.3308.  
Methyl (2S,5R)-2-allyl-10-(N-allyl-1H-indol-3-yl)-3,6-diaza-5-(tert-butoxycarbonylamino)butyl-4,7-
dioxodecanoate (18) 
This was prepared by general procedure C using 14 (0.200 g, 0.79 mmol), 15 (0.230 g), DCM (3 mL), 
AcCN (6 mL) and EDCI (0.124 g) to give 18 (130 mg, 28%) as a solid. TLC (DCM/MeOH 50:1) Rf = 
0.45; 1H NMR δ = 7.56 (d, J = 8 Hz, 1 H, ArH4), 7.27 (d, J = 8 Hz, 1 H, ArH7), 7.17 (dt, J = 8, 1 Hz, 1 
H, ArH6), 7.07 (t, J = 8 Hz, 1 H, ArH5), 6.99 (d, J = 8 Hz, 1 H, 3-NH), 6.88 (s, 1 H, ArH2), 6.34 (d, J = 
8 Hz, 1 H, 6-NH), 5.96 (ddt, J = 18, 11, 6 Hz, 1 H, NCH2CH=CH2), 5.66 (ddt, J = 17, 9, 7 Hz, 1 H, 
CHCH2CH=CH2), 5.18-5.03 (m, 4 H, 2×CH=CH2), 4.71-4.65 (m, 3 H, NCH2CH=CH2 and NHBoc), 
4.60 (dd, J = 6, 2 Hz, 1 H, H2), 4.50 (dt, J = 6, 8 Hz, 1 H, H5), 3.68 (s, 3 H, OCH3), 3.06 (d, J = 6 Hz, 2 
H, NCH2(CH2)3), 2.77 (t, J = 7 Hz, 2 H, H10), 2.52 (ddd, J = 15, 9, 5 Hz, 2 H, CHCH2CH=CH2), 2.28 (t, 
J = 7 Hz, 2 H. CH28), 2.03 (pent, J = 7 Hz, 2 H, H9), 1.81 (m, 1 H, N(CH2)3CHH), 1.63 (m, 1 H, 
N(CH2)3CHH), 1.41 (s, 9 H, C(CH3)3), 1.48-1.29 (m, 4 H, NCH2CH2(CH2)2 and N(CH2)2CH2CH2); 13C 
NMR δ = 173.2 (7-CO), 171.7 (COOCH3), 171.4 (4-CO), 156.1 (NCO2tBu), 136.4 (ArC7a), 133.6 
NCH2CH=CH2), 132.1 (CH2CH=CH2), 127.9 (ArC3a), 125.2 (ArC2), 121.4 (ArC6), 119.2 (ArC4), 
119.0 (CH2CH=CH2), 118.7 (ArC5), 117.0 (NCH2CH=CH2), 114.4 (ArC3), 109.4 (ArC7), 79.0 
(OC(CH3)3), 52.6 (C2), 52.3 (OCH3), 51.6 (C5), 48.5 (NCH2CH=CH2), 39.9 (NCH2(CH2)3), 36.2 
(CHCH2CH=CH2), 35.9 (H8), 31.9 (N(CH2)3CH2), 29.6 (NCH2CH2(CH2)2), 28.3 (C(CH3)3), 26.0 (H10), 
24.4 (H9), 22.4 (N(CH2)2CH2CH2); MS (ES) m/z 583 (100% MH+), 527 (44%), 483 (46%). HRMS (ES) 
calcd for C32H47N4O6: 583.3496; found: 583.3506.  




To a solution of 16 (0.07 g, 0.1 mmol) in DCM (2 mL) was added trifluoroacetic acid (2 mL). The 
reaction mixture was stirred under a N2 atmosphere at rt for 2 h. The solvents were evaporated and the 
residue was dissolved in methanol. Hydrochloric acid (1M, 0.2 mL, 0.2 mmol) in diethyl ether was 
added and the solution was evaporated. Recrystallization from a minimum amount of petroleum spirit 
and DCM/diethyl ether produced 25 as a brown solid in quantitative yield, Mp 103-106 °C; TLC 
(MeOH) Rf = 0.74; 1H NMR (CD3OD) δ = 7.56 (d, J = 8 Hz, 1 H, ArH4), 7.28 (d, J = 8 Hz, 1 H, ArH7), 
7.15 (s, 1 H, ArH2), 7.10 (t, J = 8 Hz, 1 H, ArH6), 7.00 (t, J = 8 Hz, 1 H, ArH5), 6.00-5.92 (m, 1 H, 
NCH2CH=CH2), 5.67-5.54 (m, 1 H, CH2CH=CH2), 5.09 (d, J = 10 Hz, 1 H, CH=CHH), 5.11-4.86 (m, 4 
H, 2×CH=CH2), 4.71 (d, J = 6 Hz, 2 H, NCH2CH=CH2), 4.37 (m, 2 H, H2 and H5), 3.68 (s, 2 H, H8), 
3.62 (s, 3 H, OCH3), 2.70 (br s, 2 H, NCH2(CH2)3), 2.49-2.41 (m, 1 H, CHCHHCH=CH2), 2.38-2.24 (m, 
1 H, CHCHHCH=CH2), 1.84-1.68 (br s, 2 H, N(CH2)3CH2), 1.68-1.46 (m, 2 H, NCH2CH2(CH2)2), 1.34-
1.22 (m, 2 H, N(CH2)2CH2CH2); 13C NMR δ = 174.1 (7-CO), 173.2 (COOCH3), 172.8 (4-CO), 137.8 
(ArC7a), 135.1 (NCH2CH=CH2), 134.0 (CH2CH=CH2), 128.9 (ArC3a), 128.4 (ArH2), 122.6 (ArH6), 
120.0 (ArH4), 119.8 (ArH5), 118.8 (CH2CH=CH2), 116.9 (N-CH2CH=CH2), 110.8 (ArH7), 109.1 
(ArC3), 54.1 (C2), 53.3 (OCH3), 52.7 (C5), 49.4 (NCH2CH=CH2), 40.4 (NCH2(CH2)3), 36.7 
(CHCH2CH=CH2), 33.8 (CH28), 32.6 (N(CH2)3CH2), 28.0 (NCH2CH2(CH2)2), 23.5 (N(CH2)2CH2CH2); 




This was prepared by general procedure D using 17 (70 mg, 0.12 mmol) giving 26 as a solid (0.050 g, 
80%). Mp 145-148 °C; TLC (MeOH) Rf = 0.67; 1H NMR δ 7.94 (br s, 1 H, 3-NH), 7.54 (d, J = 7 Hz, 1 
H, ArH4), 7.24-7.04 (m, 4 H, ArH2,5,6,7), 6.86 (br s, 1 H, 6-NH), 5.87 (m, 1 H, NCH2CH=CH2), 5.64 
(m, 1 H, CH2CH=CH2), 5.12-4.97 (m, 4 H, 2×CH=CH2), 4.62-4.44 (m, 4 H, N-CH2-CH=CH2 and H2 
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and H5), 3.64 (s, 3 H, OCH3), 3.09-2.81 (m, 4 H, H9 and NCH2(CH2)3), 2.75-2.37 (m, 4 H, H8 + 
CHCH2CH=CH2), 1.81-1.52 (m, 2 H, N(CH2)3CH2), 1.40-1.25 (m, 4 H, NCH2CH2(CH2)2 and 
N(CH2)2CH2CH2); 13C NMR δ = 175.1 (7-CO), 172.3 (COOCH3), 171.9 (4-CO), 136.3 (ArC7a), 133.5 
(NCH2CH=CH2), 132.3 (CH2CH=CH2), 127.7 (ArC3a), 125.6 (ArC2), 121.6 (ArC6), 119.2 (ArC4), 
119.0 (CH2CH=CH2), 118.9 (ArC5), 117.1 (NCH2CH=CH2), 113.1 (ArC3), 109.6 (ArC7), 52.9 (C2), 
52.5 (OCH3), 52.2 (C5), 48.6 (NCH2CH=CH2), 39.2 (NCH2(CH2)3), 36.7 (CHCH2CH=CH2), 35.8 (H8), 
31.8 (N(CH2)3CH2), 27.3 (NCH2CH2(CH2)2), 22.0 (N(CH2)2CH2CH2), 21.3 (H9); MS (ES) m/z 469 
(100% MH+). HRMS (ES) calcd for C26H37N4O4: 469.2815; found: 469.2805. 
Methyl (2S,5R)-2-allyl-10-(N-allyl-1H-indol-3-yl)-3,6-diaza-5-(4-aminobutyl)-4,7-dioxodecanoate 
hydrochloride (27) 
This was prepared by general procedure D using 18 (0.070 g, 0.12 mmol) giving 27 as a solid (0.030 g, 
47%). Mp 121-123 °C; TLC (MeOH) Rf = 0.75; 1H NMR (CD3OD) δ = 7.43 (d, J = 8 Hz, 1 H, ArH4), 
7.17 (d, J = 8 Hz, 1 H, ArH7), 7.00 (t, J = 7 Hz, 1 H, ArH6), 6.92-6.88 (m, 2 H, ArH2,5), 5.88 (ddt, J = 
17, 10, 5 Hz, 1 H, NCH2CH=CH2), 5.61 (m, 1 H, CH2CH=CH2), 5.03-4.85 (m, 4 H, 2×CH=CH2), 4.61 
(dd, J = 5 Hz, 2 H, NCH2CH=CH2), 4.37-4.26 (m, 2 H, H2 and H5), 3.56 (s, 3 H, OCH3), 3.20-3.19 (m, 
2 H, NCH2(CH2)3), 2.78* (t, J = 7 Hz, H10), 2.67 (t, J = 7 Hz, 2 H, H10), 2.51-2.29 (m, 2 H, 
CHCH2CH=CH2), 2.22 (t, J =  7 Hz, 2 H, H8), 1.89 (pent, J = 7 Hz, 2 H, N(CH2)3CH2), 1.77-1.62 (m, 1 
H, N(CH2)3CHH), 1.60-1.48 (m, 2 H, NCH2CH2(CH2)2), 1.39-1.22 (m, 2 H, N(CH2)2CH2CH2); 13C 
NMR δ = 175.2 (7-CO), 172.9 (COOCH3), 172.0 (4-CO), 136.9 (ArC7a), 134.4 (NCH2CH=CH2), 133.1 
(CH2CH=CH2), 128.2 (ArC3a), 125.5 (ArC2), 121.2 (ArC6), 118.6 (ArC4), 118.4 (CH2CH=CH2), 117.8 
(ArC5), 115.6 (NCH2CH=CH2), 114.4 (ArC3), 109.4 (ArC7), 53.0 (C2), 52.2 (OCH3), 51.6 (C5), 48.9 
(NCH2CH=CH2), 39.3 (NCH2(CH2)3), 35.6 (C8), 35.4 (CHCH2CH=CH2), 31.3 (N(CH2)3CH2), 26.9 
(C10), 24.4 (C9), 22.6 (NCH2CH2(CH2)2); MS (ES) m/z 483 (100% MH+). HRMS (ES) calcd for 
C27H39N4O4: 483.2971; found: 483.2991. 
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3.6 Ring Closing Metathesis Reaction – General Procedure E. 
Methyl (6S,9R,3E/Z)-1,3,4,5,6,7,8,9,10,11,12,13-dodecahydro-1,13-metheno-8,11-dioxo-9-(4’-tert-
butoxycarbonylaminobutyl)-2H-1,7,10-benzotriazacyclopentadecine-6-carboxylate (19) 
To a solution of 16 (0.110 g, 0.20 mmol) in DCM (50 mL) was added benzylidene-bis-
(tricyclohexylphosphine)-dichlororuthenium catalyst (0.016 g, 0.02 mmol, 10 mol%). The reaction 
mixture was heated at reflux under a N2 atmosphere for 24 h. After the solvent was evaporated, the crude 
product was chromatographed on a flash silica gel column (1% MeOH in DCM) to produce 19 (0.060 g, 
58%) as a brown amorphous solid. TLC (DCM/MeOH 10:1) Rf = 0.85; 1H NMR δ = 7.57 (d, J = 8 Hz, 1 
H, ArH14), 7.53* (d, J = 8 Hz, ArH14), 7.35* (d, J = 7 Hz, ArH17), 7.29 (d, J = 8 Hz, 1 H, ArH17), 
7.21 (t, J = 8 Hz, 1 H, ArH16), 7.11 (t, J = 8 Hz, 1 H, ArH15), 7.03 (s, 1 H, ArH18), 6.86 (d, J = 8 Hz, 1 
H, 10-NH), 6.32 (d, J = 7 Hz, 1 H, 7-NH), 6.09* (d, J = 8 Hz, 7-NH), 5.90* (m, H3), 5.52 (dt, J = 15, 6 
Hz, 1 H, H3), 4.93 (m, 1 H, H4), 4.79-4.71 (m, 2 H, CHH2 and NH-Boc), 4.63* (d, J = 5 Hz, CHH2), 
4.61-4.55 (m, 1 H, CHH2), 4.54-4.43 (m, 2 H, unresolved resonance from the (Z)-isomer and H9), 4.33 
(ddd, J = 12, 7 Hz, 1 H, H6), 3.70 (d, J = 14 Hz, 1 H, CHH12), 3.65 (s, 3 H, OCH3), 3.64* (s, OCH3), 
3.53 (d, J = 14 Hz, 1 H, CHH12), 3.11-2.99 (m, 2 H, NCH2(CH2)3), 2.45-2.22 (m, 2 H, CH25), 1.84-1.56 
(m, 4 H, N(CH2)3CH2 and NCH2CH2(CH2)2), 1.38 (s, 9 H, C(CH3)3), 1.34* (s, C(CH3)3), 1.45-1.26 (m, 2 
H, N(CH2)2CH2CH2); 13C NMR δ = 174.1 (11-CO), 172.3 (8-CO), 172.1 (COOCH3), 156.2 (NCO2tBu), 
137.2 (ArC17a), 130.5 (C3), 127.8 (ArC13a), 127.6 (C4), 126.5 (ArC17), 122.2 (ArC16), 119.7 
(ArC15), 118.8 (ArC14), 113.1 (ArC13), 109.3 (ArC18), 79.1 (OCMe3), 53.7 (C6), 52.5 (OCH3), 52.3 
(C9), 46.8 (C2), 39.8 (NCH2(CH2)3), 33.6 (C12), 32.9 (C5), 31.3 (N(CH2)3CH2), 29.7 
(NCH2CH2(CH2)2), 28.5 (C(CH3)3), 22.6 (N(CH2)2CH2CH2); MS (ES) m/z 527 (45% MH+), 471 (56%), 
453 (74%), 427 (100%). HRMS (ES) calcd for C23H31N4O4: 527.2870; found: 527.2870. 
Methyl (6S,9R,3E/Z)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-1,14-metheno-8,11-dioxo-9-
(4’-tert-butoxycarbonylaminobutyl)-1,7,10-benzotriazacyclohexadecine-6-carboxylate (20) 
   19
This was prepared by general procedure E using 17 (0.040 g, 0.07 mol), Ru catalyst (5 86 mg), and 
DCM (17.5 mL) giving 20 as a brown solid (0.038 g, 100%). TLC (DCM/MeOH 50:1) Rf = 0.68; 1H 
NMR δ = 7.55 (d, J = 8 Hz, 1 H, ArH15), 7.56* (d, J = 8 Hz, ArH15), 7.32* (d, J = 8 Hz, ArH18), 7.23 
(d, J = 8 Hz, 1 H. ArH18), 7.17 (dt, J = 8, 1 Hz, 1 H, ArH17), 7.08 (dt, J = 8, 1 Hz, 1 H, ArH16), 6.91 
(s, 1 H, ArH19), 6.88* (s, ArH19), 6.53 (d, J = 7 Hz, 1 H, 10-NH), 6.20 (d, J = 7 Hz, 1 H, 7-NH), 6.12* 
(d, 8 Hz, 7-NH), 5.96* (m, H3), 5.67 (dt, J = 16, 5 Hz, 1 H, H3), 5.56* (m, H4), 4.94 (dt, J = 16, 7 Hz, 1 
H, H4), 4.62 (dd, J = 16, 5 Hz, 2 H, CHH2), 4.56-4.51 (m, 2 H, CHH2 and NHBoc), 4.50-4.42* (m, 
H9), 4.40-4.26 (m, 2 H, H9 and H6), 3.68* (s, OCH3), 3.62 (s, 3 H, OCH3), 3.37-3.21 (m, 1 H, H13), 
3.11-2.90 (m, 4 H, NHCH2 and H13 + CH2CH13 (Z)), 2.75-2.56 (m, 3 H, H12 and CHH5), 2.55-2.38 
(m, 1 H, CHH5), 1.91-1.50 (m, 2 H, N(CH2)3CH2), 1.46-1.22 (m, 4 H, NCH2CH2(CH2)2) and 
N(CH2)2CH2CH2), 1.39 (s, 9 H, C(CH3)3), 1.32* (s, C(CH3)3), 1.23* (s, C(CH3)3); 13C NMR δ = 173.6* 
(11-CO), 173.1 (11-CO), 171.6 (8-CO), 171.4 (COOCH3), 156.3 (NCO2tBu), 136.3 (ArC18a), 130.0 
(C3), 127.5 (ArC14a), 126.2 (C4), 125.7 (ArC19), 121.6 (ArC17), 118.9 (ArC16), 118.6 (ArCH15), 
114.1 (ArC14), 109.0 (ArC18), 79.2 (OCMe3), 54.2 (C6), 52.6 (OCH3), 52.4 (C9), 46.3 (C2), 39.6 
(NCH2(CH2)3), 36.4 (C12), 33.0 (C5), 30.8* (N(CH2)3CH2), 29.8 (N(CH2)3CH2), 28.5 (C(CH3)3), 22.4 
(N(CH2)2CH2CH2), 19.6 (C13); MS (ES) m/z 541 (100% MH+), 485 (56%). HRMS (ES) calcd for 
C29H41N4O6: 541.3026; found: 541.3014. 
Methyl (6S,9R,3E/Z)-1,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1,15-metheno-8,11-dioxo-9-
(4’-tert-butoxycarbonylaminobutyl)-2H-1,7,10-benzotriazacycloheptadecine-6-carboxylate (21) 
This was prepared by general procedure E using 18 (0.80 g, 0.014 mmol), Ru cat (11.4 mg) and DCM 
(24 mL) giving 21 as a brown solid (0.013 g, 13%). TLC (DCM/MeOH 50:1) Rf = 0.59; 1H NMR δ = 
7.54* (d, J = 8 Hz, 1 H, ArH16), 7.55 (d, J = 8 Hz, 1 H, ArH16), 7.33-7.03 (m, 3 H, ArH17,18,19), 6.88 
(s, 1 H, ArH20), 6.84 (d, J = 8 Hz, 1 H, 10-NH), 6.74* (s, ArH20), 6.44 (d, J = 6 Hz, 1 H, 7-NH), 5.96-
5.89* (m, H3), 5.88-5.71 (m, 1 H, H3), 5.59-5.36 (m, 1 H, H4), 4.73-4.38 (m, 4 H, H2 and H9 and H6), 
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3.73* (s, OCH3), 3.68* (s, OCH3), 3.67* (s, OCH3), 3.66 (3H, s, OCH3), 3.06-2.89 (m, 2 H, ArH14), 
2.88-2.79* (m, H14), 2.78-2.70 (m, 2 H, H2), 2.66-2.48 (m, 2 H, H12), 2.32-2.14 (m, 2 H, H5), 2.03-
1.94 (m, 2 H, H13), 1.82-1.58 (m, 2 H, N(CH2)3CH2), 1.44-1.23 (m, 4 H, NCH2CH2(CH2)2 and 
N(CH2)2CH2CH2), 1.41-1.38 (m, 9 H, C(CH3)3); 13C NMR δ = 174.4 (11-CO), 173.3 (8-CO), 171.9 
(COOCH3), 156.0 (NCO2tBu), 136.3 (ArC19a), 130.1 (C3), 128.9 (ArC15a), 127.9* (ArCH15a), 125.0 
(ArC20), 121.6 (ArC18), 119.1 (ArC17), 118.8 (ArC16), 113.8 (C15), 108.9 (CH19), 79.1 (OCMe3), 
53.4 (C6), 52.5 (OCH3), 52.0 (C9), 46.8 (C2), 40.7 (NCH2(CH2)3), 33.8 (C12), 32.7 (C5), 31.3 
(N(CH2)3CH2), 29.7 (NCH2CH2(CH2)2), 28.5 (C(CH3)3), 23.2 (C14), 22.7 (N(CH2)2CH2CH2), 21.8 
(C13); MS (ES) m/z 555 (100% MH+), 297 (53%). HRMS (ES) calcd for C30H43N4O6: 555.3183; found: 
555.3187. 
3.7 Amino Acid Deprotection – General Procedure F. 
Methyl (6S,9R,3E/Z)-1,3,4,5,6,7,8,9,10,11,12,13-dodecahydro-1,13-metheno-8,11-dioxo-9-(4-
aminobutyl)-2H-1,7,10-benzotriazacyclopentadecine-6-carboxylate hydrochloride (22) 
To a solution of 19 (0.08 g, 0.011 mmol) in DCM (2 mL) was added trifluoroacetic acid (2 mL). The 
reaction mixture was stirred under a N2 atmosphere at rt for 2 h. After the removal of solvent, DCM was 
added and the solution was re-evaporated. The residue was dissolved in methanol (5 mL), and then a 
soln of HCl (1M, 0.3 mL, 0.3 mmol, 2 molar equiv) in diethyl ether was added. The solvents were then 
evaporated. The product was precipitated from diethyl ether and a minimum amount of petroleum spirit 
followed by DCM to give 22 (0.06 g, 86%) as a brown solid. mp 168-170 °C; TLC (MeOH) Rf = 0.81; 
1H NMR (CD3OD, 500 MHz) δ = 7.39 (d, J = 8 Hz, 1 H, ArH14), 7.27* (d, J = 8 Hz, ArH17), 7.21 (d, J 
= 8 Hz, 1 H, ArH17), 6.98 (t, J = 8 Hz, 1 H, ArH16), 6.93 (s, 1 H, ArH18), 6.88 (t, J = 8 Hz, 1 H, 
ArH15), 5.78* (dd, J = 10, 5 Hz, H3), 5.52 (dt, J = 15, 5 Hz, 1 H, H3), 5.40* (dd, J = 10, 5 Hz, H4), 
4.88-4.83 (dt, J = 15, 8 Hz, 1 H, H4), 4.59 (dd, J = 9, 3 Hz, 1 H, CHH2), 4.36 (dd, J = 9, 6 Hz, 1 H, 
CHH2), 4.20 (t, J = 7 Hz, 1 H, H9), 4.10 (dd, J = 9, 5 Hz, 1 H, H6), 3.67 (d, J = 9 Hz, 1 H, CHH12), 
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3.51 (s, 3 H, OCH3), 3.31 (d, J = 9 Hz, 1 H, CHH12), 2.74 (dd, 2 H, NCH2(CH2)3), 2.51-2.42* (m, 
CHH5), 2.41-2.34 (m, 1 H, CHH5), 2.12 (ddd, J = 14, 6 Hz, 1 H, CHH5), 1.69-1.49 (m, 2 H, 
N(CH2)3CH2), 1.58-1.48 (m, 2 H, NCH2CH2(CH2)2), 1.36-1.23 (m, 2 H, N(CH2)2CH2CH2); 13C NMR 
(CD3OD) δ = 174.9 (11-CO), 174.8 (8-CO), 173.2 (COOCH3), 138.7 (ArC17a), 131.6 (C3), 129.2 
(ArC13a), 129.2 (C4), 127.8 (ArC18), 122.5 (ArC16), 120.3 (ArC15), 119.6 (ArC14), 111.1 (ArC13), 
110.3 (ArC17), 55.9 (C6), 54.4 (OCH3), 52.8 (C9), 47.5 (C2), 40.5 (NCH2(CH2)3), 33.9 (C12), 33.5* 
(C12), 32.2 (N(CH2)3CH2), 27.9 (NCH2CH2(CH2)2), 23.7 (N(CH2)2CH2CH2); MS (ES) m/z 427 (100% 
MH+). HRMS (ES) calcd for C23H31N4O4: 427.2345; found: 427.2343.  
Methyl (6S,9R,3E/Z)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-1,14-metheno-8,11-dioxo-9-(4-
aminobutyl)-1,7,10-benzotriazacyclohexadecine-6-carboxylate hydrochloride (23) 
This was prepared by general procedure F using 20 (0.15 g, 0.28 mmol), TFA (3 mL) and DCM (3 mL) 
giving 23 (0.120 g, 91%). Mp 176-179 °C; TLC (MeOH) Rf = 0.76; 1H NMR (CD3OD, 500 MHz) δ = 
8.20* (d, J = 8 Hz, 10-NH), 8.00 (d, J = 7 Hz, 1 H, 10-NH), 7.78 (d, J = 7 Hz, 1 H, 7-NH), 7.59* (d, J = 
7 Hz, 7-NH), 7.53 (d, J = 7 Hz, 1 H, ArH15), 7.51 (d, J = 8 Hz, 1 H, ArH15), 7.38* (d, J = 8 Hz, 
ArH18), 7.26 (d, J = 8 Hz, 1 H, ArH18), 7.15* (t, J = 7 Hz, ArH17), 7.10 (t, J = 7 Hz, 1 H, ArH17), 
7.03* (t, J = 7 Hz, ArH16), 7.01 (t, J = 7 Hz, 1 H, H16), 6.94* (s, ArH19), 6.93 (s, 1 H, ArH19), 5.86-
5.75* (m, H3), 5.79-5.72 (dt, J = 16, 4 Hz, 1 H, H3), 5.59-5.51* (dt, J = 10, 5 Hz, H4), 4.95-4.85 (m, 1 
H, H4), 4.78-4.70 (dd, J = 16, 3 Hz, 1 H, CHH2), 4.73-4.66* (m, CHH2), 4.61-4.54* (m, CHH2), 4.52 
(dd, J = 16, 5 Hz, 1 H, CHH2), 4.52-4.46* (m, H6), 4.45-4.39* (m, H9), 4.30-4.24 (m, 1 H, H9), 4.21-
4.14 (m, 1 H, H6), 3.71* (s, OCH3), 3.65 (s, 3 H, OCH3), 3.27-3.14 (m, 2 H, H13), 2.99-2.89* (m, H13), 
2.98-2.87* (m, CHH5), 2.97-2.86 (m, 2 H, NCH2(CH2)3), 2.72-2.61* (m, CHH5), 2.71-2.60 (m, 2 H, 
H12), 2.57-2.49 (m, 1 H, CHH5), 2.37-2.28 (m, 1 H, CHH5), 1.88-1.78* (m, N(CH2)3CHH), 1.74-1.65* 
(m, N(CH2)3CHH), 1.80-1.60 (m, 2 H, N(CH2)3CH2), 1.73-1.62 (m, 2 H, NCH2CH2(CH2)2), 1.55-1.36 
(m, 2 H, N(CH2)2CH2CH2); 13C NMR δ = 174.3 (11-CO), 174.2* (11-CO), 174.0 (8-CO), 173.8* (8-
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CO), 172.1 (COOCH3), 171.8* (COOCH3), 136.7 (ArC18a), 129.6 (C3), 127.9 (ArC14a), 127.3* (C4), 
126,4 (C4), 125.7 (ArC19), 121.5 (ArC17), 121.4 (ArC17), 118.6 (ArC16), 118.3 (ArC15), 113.8 
(ArC14), 109.2 (ArC18), 109.0* (ArC18), 54.6 (C6), 53.6* (C6), 53.4 (C9), 52.5* (C9), 52.1* (OCH3), 
51.9 (OCH3), 46.3 (C2), 41.2* (C2), 39.4 (NCH2(CH2)3), 35.7 (C12), 32.3 (C5), 32.0* (N(CH2)3CH2), 
31.5 (N(CH2)3CH2), 28.5* (C5), 26.9 (NCH2CH2(CH2)2), 22.6 (N(CH2)2CH2CH2), 20.4 (C13); MS (ES) 
m/z 441 (100% MH+). HRMS (ES+) calcd for C24H33N4O4: 541.3026; found: 541.3014.  
Methyl (6S,9R,3E/Z)-1,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1,15-metheno-8,11-dioxo-9-
(4-aminobutyl)-2H-1,7,10-benzotriazacycloheptadecine-6-carboxylate hydrochloride (24) 
This was prepared by general procedure F using 21 (0.90 g, 0.16 mmol), TFA (2 mL) and DCM (2 mL) 
giving 24 (0.050 g, 63%). mp 156-159 °C; TLC (MeOH) Rf = 0.69; 1H NMR (CD3OD, 500 MHz) δ = 
7.43 (d, J = 8 Hz, 1 H, ArH16), 7.30* (d, J = 8 Hz, ArH19), 7.25 (d, J = 8 Hz, 1 H, ArH19), 7.07* (t, J = 
8 Hz, ArH18), 7.03 (t, J = 8 Hz, 1 H, ArH18), 6.91 (t, J = 8 Hz, 1 H, ArH17), 6.76 (s, 1 H, ArH20), 
6.70* (s, ArH20), 5.82-5.75 (m, 1 H, H3), 5.61-5.53* (m, H3), 5.52-5.44 (dt, J = 5, 8 Hz, 1 H, H4), 
4.35-4.24* (m, H4), 4.65-4.59 (dd, J = 5, 3 Hz, 1 H, CHH2), 4.49* (d, CHH2), 4.44-4.41* (d, CHH2), 
4.38 (apparent t, J = 7 Hz, 1 H, CHH2), 4.35-4.26 (m, 1 H, CH9), 4.20 (dd, J = 9, 2 Hz, 1 H, H6), 3.66* 
(s, OCH3), 3.62 (s, 3 H, OCH3), 2.84-2.77 (m, 4 H, H14 and NCH2(CH2)3), 2.38-2.29 (m, 2 H, H12), 
2.21 (dt, J = 16, 5 Hz, 1 H, CHH5), 2.13-2.05 (m, 1 H, CHH5), 1.97-1.80 (m, 2 H, H13), 1.75-1.50 (m, 2 
H, N(CH2)3CH2), 1.57 (m, 2 H, NCH2CH2(CH2)2), 1.41-1.26 (m, 2 H, N(CH2)2CH2CH2), 13C NMR, δ = 
175.0 (12-CO), 174.9 (8-CO), 173.3 (COOCH3), 172.9* (COOCH3), 138.0 (ArC19a), 131.4 (C3), 129.4 
(ArC15a), 128.9 (C4), 126.6 (ArC20), 122.3 (ArC18), 119.8 (ArC17), 119.6 (ArC16), 119.5 (ArC16), 
114.2 (ArC15), 110.0 (ArCH17), 54.6 (CHN), 54.4 (OCH3), 53.0 (CHN), 47.4 (CH22), 40.4 
(NCH2(CH2)3), 34.3 (C12), 33.3 (C5), 32.6 (N(CH2)3CH2), 27.8 (NCH2CH2(CH2)2), 23.7 (C14), 23.5 
(N(CH2)2CH2CH2), 23.1 (CH213); MS (ES) m/z 455 (100% MH+). HRMS (ES) calcd for C25H35N4O4: 
455.2658; found: 455.2647. 
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To a solution of N,N′-diBoc-N-triflylguanidine (0.024 g, 0.06 mmol) in DCM was added 22 (0.03 g, 
0.06 mmol) and triethylamine (9.0 μL, 0.06 mmol). Triethylamine (0.1 mL) in DCM (0.9 mL) was pre-
prepared and a portion (0.1 mL) of this soln was taken for the reaction. The reaction mixture was stirred 
under a N2 atmosphere at rt for 3 h. The solvent was evaporated and the reaction mixture was diluted 
with DCM and washed with sodium bisulfate (2M), saturated sodium bicarbonate and brine, dried and 
evaporated giving 28 (20 mg, 46%). 1H NMR (CD3OD, 500 MHz) δ = 7.66 (d, J = 8 Hz, 1 H, ArH14), 
7.31 (d, J = 8 Hz, 1 H, ArH17), 7.23 (t, J = 8 Hz, 1 H, ArH16), 7.15 7.23 (t, J = 8 Hz, 1 H, ArH15), 7.08 
(s, 1 H, ArH18), 6.36 (d, J = 5 Hz, 1 H, 10-NH), 6.04 (d, J = 5 Hz, 1 H, 7-NH), 5.61 (dt, J = 16, 5 Hz, 1 
H, H3), 4.91 (dt, J = 16, 7 Hz, 1 H, H4), 4.60 (d, J = 6 Hz, 2 H, H2), 4.52 (dt, J = 12, 6 Hz, 1 H, H9), 
4.43 (dd, J = 13, 6 Hz, 1 H, H6), 3.69* (s, OCH3), 3.67 (s, 3 H, OCH3), 3.64-3.62 (m, 2 H, H12), 3.37 
(dt, J = 8, 5 Hz, 2 H, NHCH2), 2.39 (dd, J = 4 Hz, 2 H, H5), 1.90-1.40 (m, 4 H, 2×CH2), 1.51 (s, 9 H, 
C(CH3)3), 1.47* (s, C(CH3)3); 13C NMR δ = 171.9 (11-CO), 171.7 (8-CO), 163.4 (COOCH3), 162.1* 
(COOCH3), 156.0* (NCO2tBu), 151.2 (NCO2tBu), 137.4 (ArC17a), 130.7 (C2), 127.8 (ArC13a), 127.1 
(C4), 126.5 (ArCH18), 122.5 (ArCH16), 121.3 (ArCH15), 117.0 (ArC13), 112.8 (ArC14), 109.5 
(ArC17), 86.0 (CNHBoc), 83.1* (NCMe3), 79.1 (OCMe3), 53.7 (C6), 52.8 (OCH3), 52.6 (C9), 46.9 
(C2), 40.6 (NCH2(CH2)3), 33.7 (C12), 32.9 (CH5), 31.4 (N(CH2)3CH2), 29.7 (NCH2CH2(CH2)2), 28.4, 
28.1 and 27.9 (C(CH3)3), 22.9 (N(CH2)2CH2CH2); MS (ES) m/z 669 (27% MH+). HRMS (ES) calcd for 





This was prepared by general procedure G using 23 (0.050 g, 0.11 mmol), N,N′-diBoc-N-
triflylguanidine (0.040 g) and triethylamine (15 μL) giving 29 (0.060 g, 84%). TLC (DCM/MeOH 50:1) 
Rf = 0.20; 1H NMR δ = 8.28 (br s, 1 H, NHBoc), 7.55 (d, J = 8 Hz, 1 H, ArH15), 7.31* (d, J = 8 Hz, 
ArH15), 7.23 (d, J = 8 Hz, 1 H, ArH18), 7.17 (dt, J = 8, 1 Hz, 1 H, ArH17), 7.08 (dt, J = 8, 1 Hz, 1 H, 
ArH16), 6.91 (s, 1 H, ArH19), 6.88* (s, ArH19), 6.68 (d, J = 8 Hz, 1 H, 10-NH), 6.18* (d, J = 8 Hz, 7-
NH), 6.02 (d, J = 8 Hz, 1 H, 7-NH), 5.95* (m, H3), 5.65 (dt, J = 15, 5 Hz, 1 H, H3), 4.97 (dt, J = 15, 8 
Hz, 1 H, H4), 4.68-4.44 (m, 3 H, H2 and H9), 4.41-4.33 (m, 1 H, H6), 3.67* (s, OCH3), 3.63 (s, 3 H, 
OCH3), 3.36-3.24 (m, 2 H, H13), 3.03-2.92 (m, 1 H, CHH5), 2.75-2.72* (m, CHH5), 2.71-2.67 (m, 1 H, 
CHH5), 2.59-2.54 (m, 2 H, N(CH2)3CH2), 2.46 (dd, J = 13, 6 Hz, 2 H, NCH2CH2(CH2)2), 1.95-1.83 (m, 
2 H, N(CH2)2CH2CH2), 1.47 (s, 18 H, C(CH3)3), 1.45* (s, C(CH3)3); 13C NMR δ = 172.9 (11-CO), 171.4 
(8-CO), 171.3 (COOCH3), 163.4 (ArC), 156.0 and 153.1 (NCO2But), 136.3 (ArC18a), 130.1 (C3), 127.5 
(ArC14a), 126.3 (C4), 125.5 (ArCH19), 121.6 (ArCH17), 118.9 (ArCH16), 118.5 (ArCH15), 114.1 
(ArC14), 109.0 (ArCH18), 83.1 (CNHBoc), 79.3 (OCMe3), 54.1 (C6), 52.5 (OCH3), 52.4 (C9), 46.3 
(C2), 40.5 (NCH2(CH2)3), 36,4 (C12), 33.0 (C5), 31.0 (N(CH2)3CH2), 29.8 (NCH2CH2(CH2)2), 28.4 and 
28.1 (C(CH3)3), 23.1 (N(CH2)2CH2CH2), 19.7 (ArC13); MS (ES) m/z 683 (23% MH+). HRMS (ES) 




This was prepared by general procedure G using 24 (0.030 g, 0.06 mmol), N,N′-diBoc-N-
triflylguanidine (0.023 g) and triethylamine (8.5 μL) to give 30 (30 mg, 70%). TLC (DCM/MeOH 50:1) 
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Rf = 0.20; 1H NMR (CDCl3, 500 MHz) δ = 8.26 (s, 1 H, NHBoc), 7.56 (d, J = 8 Hz, 1 H, ArH16), 7.32* 
(d, J = 8 Hz, ArH19), 7.24-7.16 (m, 2 H, ArH18,19), 7.08 (t, J = 7 Hz, 1 H, ArH17), 6.87 (s, 1 H, 
ArH20), 6.74* (s, ArH20), 6.43 (d, J = 7 Hz, 1 H, 10-NH), 6.38* (d, J = 7 Hz, 7-NH), 5.94* (m, H3), 
5.80-5.71 (m, 1 H, H3), 5.65 (d, J = 9 Hz, 1 H, 7-NH), 5.54* (m, H4), 5.43 (dt, J = 15, 9 Hz, 1 H, H4), 
4.68-4.57 (m, 2 H, CHH2 and H9), 4.50-4.43 (m, 2 H, CHH2 and H6), 3.73* (s, OCH3), 3.68 (s, 3 H, 
OCH3), 3.39-3.31 (m, 2 H, H14), 3.03-2.97 (m, 2 H, NCH2(CH2)3), 2.89-2.81 (m, 2 H, H12), 2.75* (m, 
H12), 2.60-2.49 (m, 2 H, H5), 2.30-2.24 (m, 2 H, H13), 2.18-1.97 (m, 2 H, N(CH2)3CH2), 2.00-1.99 (m, 
2 H, NCH2CH2(CH2)2), 1.97-1.80 (m, 2 H, N(CH2)2CH2CH2), 1.60 (s, 9 H, C(CH3)3), 1.46 and 1.45* 
(9H, C(CH3)3); 13C NMR δ = 173.2 (11-CO), 171.7 (8-CO), 171.6 (COOCH3), 163.3 (ArC), 156.0 
(NCO2tBu), 153.1* (NCO2tBu), 136.3 (ArC19a), 130.1 (C3), 128.2 (ArC15a), 127.8 (C4), 126.4* (C4), 
124.9 (ArC20), 121.6 (ArC18), 119.1 (ArC17), 118.9 (ArC16), 113.8 (ArC15), 108.9 (ArC19), 83.1 
(CNHBoc), 79.3 (OCMe3), 53.7 (C6), 52.5 (OCH3), 51.9 (C9), 46.8 (C2), 40.4 (NCH2(CH2)3), 33.7 
(C12), 32.7 (C5), 31.5 (N(CH2)3CH2), 29.8 (NCH2CH2(CH2)2), 28.3 and 28.1 (C(CH3)3), 23.2 (C14), 
23.0 (N(CH2)2CH2CH2), 21.9 (C13); MS (ES) m/z 697 (100% MH+). HRMS (ES) calcd for C36H53N6O8: 
697.3925; found: 697.3943. 
3.9 Guanidation Deprotection – General Procedure H. 
Methyl (6S,9R,3E/Z)-1,3,4,5,6,7,8,9,10,11,12,13-dodecahydro-1,13-metheno-8,11-dioxo-9-(4-
guanidylbutyl)-2H-1,7,10-benzotriazacyclopentadecine-6-carboxylate hydrochloride (31) 
To a solution of 28 (0.010 g, 0.11 mmol) in DCM (2 mL) was added trifluoroacetic acid (4 mL). The 
reaction mixture was stirred under a N2 atmosphere at rt for 2 h. The solution was evaporated and the 
crude product dissolved in methanol (5 mL). Hydrochloric acid (0.3 mL, 0.3 mmol, 2 molar equiv, 1M) 
in diethyl ether was added and the solvent was then evaporated. Recrystallization from a minimum 
amount of petroleum spirit and DCM/diethyl ether gave 31 (0.006 g, 11%) as a brown solid. mp 151-154 
°C; 1H NMR (CD3OD, 500 MHz) δ = 7.59 (d, J = 8 Hz, 1 H, ArH14), 7.47* (d, J = 8 Hz, ArH17), 7.41 
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(d, J = 8 Hz, 1 H, ArH17), 7.18 (m, 1 H, ArH16), 7.10 (m, 2 H, ArH15,18), 5.99* (m, H3), 5.70 (dt, J = 
15, 6 Hz, 1 H, H3), 5.62-5.58* (m, H4), 5.06 (dt, J = 15, 9 Hz, 1 H, H4), 4.89 (m, 1 H, CHH2), 4.59 (dd, 
J = 16, 7 Hz, 1 H, CHH2), 4.42 (dd, J = 9, 7 Hz, 1 H, H9), 4.33 (dd, J = 10, 4 Hz, 1 H, H6), 3.81 (d, J = 
15 Hz, 1 H, CHH12), 3.70 (s, 3 H, OCH3), 3.64* (s, OCH3), 3.53 (d, J = 9 Hz, 1 H, CHH12), 3.19-3.16 
(m, 2 H, NCH2(CH2)3), 2.57 (dt, J = 8, 3 Hz, 1 H, CHH5), 2.35-2.26 (m, 1 H, CHH5), 1.86-1.80 (m, 2 
H, N(CH2)3CH2), 1.69-1.60 (m, 2 H, NCH2CH2(CH2)2), 1.49-1.42 (m, 2 H, N(CH2)2CH2CH2); MS (ES) 
m/z 469 (100% MH+). HRMS (ES) calcd for C24H33N6O4: 469.2563; found: 469.2576. 
Methyl (6S,9R,3E/Z)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-1,14-metheno-8,11-dioxo-9-(4-
guanidylbutyl)-1,7,10-benzotriazacyclohexadecine-6-carboxylate hydrochloride (32) 
This was prepared by general procedure H using 29 (0.020 g, 0.03 mmol), TFA (4 mL) and DCM (2 
mL) to give 32 (0.010 g, 73%). mp 176-179 °C; 1H NMR (CD3OD, 500 MHz) δ = 7.47 (d, J = 8 Hz, 1 
H, ArH15), 7.32* (d, J = 8 Hz, ArH18), 7.21 (d, J = 8 Hz, 1 H, ArH18), 7.11-6.92 (m, 2 H, ArH16,17), 
6.86 (s, 1 H, ArH19), 5.71 (dt, J = 15, 5 Hz, 1 H, H3), 4.87-4.62 (m, 1 H, H4), 4.57-4.46 (m, 1 H, 
CHH2), 4.44-4.33 (m, 1 H, CHH2), 4.20 (t, J = 8 Hz, 1 H, H9), 4.12 (dd, J = 11, 4 Hz, 1 H, H6), 3.65* 
(s, OCH3), 3.59 (s, 3 H, OCH3), 3.25-3.13 (m, 2 H, H13), 3.11-3.06 (m, 2 H, NCH2(CH2)3), 2.96-2.82 
(m, 2 H, H12), 2.61-2.43 (m, 1 H, CHH5), 2.35-2.20 (m, 1 H, CHH5), 1.74-1.63 (m, 2 H, N(CH2)3CH2), 
1.58-1.47 (m, 4 H, NCH2CH2(CH2)2 and N(CH2)2CH2CH2); MS (ES) m/z 484 (100% MH+). HRMS 
(ES) calcd for C25H36N6O4: 484.2798; found: 484.2805. 
Methyl (6S,9R,3E/Z)-1,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1,15-metheno-8,11-dioxo-9-
(4-guanidylbutyl)-2H-1,7,10-benzotriazacycloheptadecine-6-carboxylate hydrochloride (33) 
This was prepared by general procedure H using 30 (0.020 g, 0.03 mmol), TFA (4 mL) and DCM (2 
mL) to give 33 (0.010 g, 73%), as a light brown solid. Mp >228 °C. 1H NMR (CD3OD, 500 MHz) δ = 
7.62* (d, J = 8 Hz, ArH16), 7.45 (d, J = 8 Hz, 1 H, ArH16), 7.32* (d, J = 8 Hz, ArH19), 7.27 (1H, d, J = 
8 Hz, ArH19), 7.07-7.01 (m, 1 H, ArH18), 6,92 (t, J = 8 Hz, 1 H, ArH17), 6.79 (s, 1 H, ArH20), 6.72* 
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(s, ArH20), 5.83-5.76 (m, 1 H, H3), 5.68-5.56* (m, H3), 5.62-5.48 (m, 1 H, H4), 5.34-5.30* (m, H4), 
4.84-4.63 (m, 2 H, H2), 4.41-4.31 (m, 1 H, H9), 4.25-4.21 (m, 1 H, H6), 3.68* (s, OCH3), 3.64 (s, 3 H, 
OCH3), 3.07 (apparent t, J = 6 Hz, 2 H, NCH2(CH2)3), 2.82-2.81 (m, 1 H, CHH14), 2.65-2.62 (m, 2 H, 
H12), 2.34-2.32 (m, 2 H, H5), 2.22 (dt, J = 10, 3 Hz, 1 H, CHH14), 2.12-2.08 (m, 2 H. H13), 1.98-1.88 
(m, 2 H, N(CH2)3CH2), 1.72-1.66 (m, 2 H, NCH2CH2(CH2)2), 1.56-1.51 (m, 2 H, N(CH2)2CH2CH2); MS 
(ES) m/z 497 (100% MH+). HRMS (ES) calcd for C26H37N6O4: 497.2876; found: 497.2878. 
2.2.1. Antibacterial  Testing 
Antibacterial testing against Staphylococcus aureus ATCC6538P was performed at Amrad Corporation 
Ltd, Melbourne, Australia. 
Assay procedure: A standardised inoculate for assays was prepared in 1/10 dilution of seed culture. To a 
96 well microtitre plate was added 50 μL of liquid medium [Mueller-Hinton broth medium (MHB) and 
Mueller-Hinton agar medium (MHA)]. The peptoid compounds were dissolved in a 50% MeOH/H2O 
solution for the final concentration of 1 mg/mL. Test solution (50 μL) was added into the top row of the 
plate. A dilution series was continued until it reached the last row of the plate the excess was discarded. 
The plates (2 peptoid samples were tested per plate) were incubated at 37 °C and shaken at 100 rpm for 
18 h. 
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